1.6.7 Other drugs used in constipation
Linaclotide is licensed for use in moderate to severe IBS with constipation. It can be used where optimal or maximum tolerated doses of previous laxatives from different classes have not helped and where constipation has been present for at least 12 months. The effectiveness of linaclotide should be reviewed after 3 months. See NICE Clinical Guideline 61: Irritable Bowel Syndrome in Adults (Feb 2015) for other treatment options.
Lubiprostone and Prucalopride are newer treatments licensed for use in chronic constipation.
Lubiprostone is an option for treating chronic idiopathic constipation, in adults in whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and for whom invasive treatment for constipation is being considered NICE TA 318 (July 2014)
Prucalopride is licensed for use in women only and is recommended as an option for the treatment of chronic constipation only in women for whom treatment with at least two laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered. NICE TA 211 (Dec 2010)